# A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

> **NCT06541847** · PHASE2 · RECRUITING · sponsor: **Healx Limited** · enrollment: 25 (estimated)

## Conditions studied

- Neurofibromatosis Type 1

## Interventions

- **DRUG:** HLX-1502

## Key facts

- **NCT ID:** NCT06541847
- **Lead sponsor:** Healx Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2027-06
- **Final completion:** 2028-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06541847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06541847, "A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06541847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*